drugset / Trial / NCT04930549
Vascular Impact of Dapagliflozin in CKD Patients (DAPAVASC)
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This study aims to determine whether dapaglfiflozin 12-week administration is associated with a beneficial impact on the vasculature of patients with chronic kidney disease.
Timeline
- Start
- 2022-10-18
- Primary completion
- 2024-09-23
- Completion
- 2024-09-23
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dapagliflozin | Small molecule | 10 mg | — |